Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Nov 20 (Reuters) - Kura Oncology KURA.O said on
Wednesday it will collaborate with Japan's Kyowa Kirin 4151.T
to develop and commercialize the blood cancer therapy
ziftomenib.
Kura said it will receive an upfront payment of $330 million
and up to $1.2 billion in total milestone payments as part of
the deal.
(Reporting by Christy Santhosh in Bengaluru; Editing by
Mohammed Safi Shamsi)
((Christy.Santhosh@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia